BioNTech Posts Lower 4Q Revenue, Profit; Sees Fall in Covid-Vaccine Sales
By Cecilia Butini
BioNTech SE on Monday posted lower revenue and profit for the fourth quarter of 2022, and said it expects a fall in revenue from its Covid-19 vaccines in the current year.
The Germany-based biotechnology company posted net profit of 2.28 billion euros ($2.45 billion) in the final quarter of the year, down from EUR5.53 billion the year prior, on revenue which slid to EUR4.28 billion from EUR3.17 billion in the same quarter of 2021. Diluted earnings per share also fell to EUR9.26 from EUR12.18 in the fourth quarter of 2021, the company said.
In 2023, BioNTech expects Covid-19 vaccine revenue to total about EUR5 billion, based on an expected transition from an advanced purchase agreement environment to commercial market ordering, the company said. For 2022, the company had guided for revenue from Covid-19 vaccines of between EUR13 billion and EUR17 billion.
"While a vaccine adaptation is expected to lead to an increased demand, fewer primary vaccinations and lowered population-wide levels of boosting are anticipated," it added.
In 2022, the company invoiced about 2 billion doses of its Covid-19 shot Comirnaty, including about 550 million of its Omicron-adapted bivalent vaccine, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 27, 2023 07:35 ET (11:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth